Basic study on SH2 domain of Grb2 as a molecular probe for detection of RTK activation

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 281-287

  Saito, Yuriko ^a,c   Furukawa, Takako ^a,b   Arano, Yasushi ^c   Fujibayashi, Yasuhisa ^a,b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Epidermal growth factor receptor; Grb2; Receptor tyrosine kinase activation; SH2 domain

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HYBRID PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CELL; DRUG TARGETING; ENZYME ACTIVATION; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR PROBE; NEOPLASM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; BIOLOGICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETIC PROCEDURES; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; SRC HOMOLOGY DOMAIN; TUMOR CELL CULTURE;

DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GRB2 ADAPTOR PROTEIN; GREEN FLUORESCENT PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR PROBE TECHNIQUES; MOLECULAR PROBES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; SRC HOMOLOGY DOMAINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 77954167742     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000676     Document Type: Article

References (35)

1. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990. (Pubitemid 20149352)
2. Kaushansky A, Gordus A, Chang B, Rush J and MacBeath G: A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. Mol Biosyst 4: 643-653, 2008.
3. Sundaram MV: RTK/Ras/MAPK signaling. WormBook 1-19, 2006.
4. Schulze WX, Deng L and Mann M: Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005.0008, 2005.
5. Machida K and Mayer BJ: The SH2 domain: Versatile signaling module and pharmaceutical target. Biochim Biophys Acta 1747: 1-25, 2005.
6. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
7. Robertson SC, Tynan JA and Donoghue DJ: RTK mutations and human syndromeswhen good receptors turn bad. Trends Genet 16: 265-271, 2000.
8. Zwick E, Bange J and Ullrich A: Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8: 161-173, 2001. (Pubitemid 32947638)
9. Niu G and Chen X: PET imaging of angiogenesis. PET Clin 4: 17-38, 2009.
10. Snyder EL, Saenz CC, Denicourt C, et al: Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res 65: 10646-10650, 2005.
11. Kim D, Jeon C, Kim JH, et al: Cytoplasmic transduction peptide (CTP): New approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res 312: 1277-1288, 2006.
12. Jones SW, Christison R, Bundell K, et al: Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol 145: 1093-1102, 2005. (Pubitemid 43079982)
13. Katterle Y, Brandt BH, Dowdy SF, Niggemann B, Zanker KS and Dittmar T: Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-ErbB-2-positive breast cancer cells. Br J Cancer 90: 230-235, 2004.
14. Janne PA, Engelman JA and Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23: 3227-3234, 2005. (Pubitemid 46211347)
15. Greulich H, Chen TH, Feng W, et al: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: E313, 2005. (Pubitemid 41735785)
16. Wikstrand CJ, Hale LP, Batra SK, et al: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148, 1995.
17. Graveel CR, DeGroot JD, Su Y, et al: Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 106: 12909-12914, 2009.
18. Ostrowski J, Polkowski M, Paziewska A, et al: Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to kit mutations and expression. BMC Cancer 9: 413, 2009.
19. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
20. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ and Bigner DD: Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324: 855-861, 1997.
21. Matuoka K, Shibata M, Yamakawa A and Takenawa T: Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries. Proc Natl Acad Sci USA 89: 9015-9019, 1992.
22. Burke P, Schooler K and Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12: 1897-1910, 2001.
23. Yamazaki T, Zaal K, Hailey D, Presley J, Lippincott-Schwartz J and Samelson LE: Role of Grb2 in EGF-stimulated EGFR internalization. J Cell Sci 115: 1791-1802, 2002. (Pubitemid 34567241)
24. Jiang X, Huang F, Marusyk A and Sorkin A: Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14: 858-870, 2003. (Pubitemid 36337438)
25. Seiden-Long I, Navab R, Shih W, et al: Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis 29: 647-655, 2008. (Pubitemid 351404883)
26. Li W, Li F, Huang Q, Frederick B, Bao S and Li CY: Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. Cancer Res 68: 4990-4997, 2008.
27. Schwarze SR, Ho A, Vocero-Akbani A and Dowdy SF: In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285: 1569-1572, 1999.
28. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA and Tsien RY: Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 101: 17867-17872, 2004.
29. Fischer R, Kohler K, Fotin-Mleczek M and Brock R: A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J Biol Chem 279: 12625-12635, 2004.
30. Prochiantz A: Messenger proteins: Homeoproteins, TAT and others. Curr Opin Cell Biol 12: 400-406, 2000.
31. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F and Cardoso MC: Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J 20: 1775-1784, 2006.
32. Fittipaldi A, Ferrari A, Zoppe M, et al: Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278: 34141-34149, 2003.
33. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44: 1962-1969, 2003.
34. 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35: 958-965, 2008.
35. Giubellino A, Burke TR Jr and Bottaro DP: Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets 12: 1021-1033, 2008.